CBI

Clal Biotechnology Industries – a leading Israeli life sciences investment company

about cbi

Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI). CBI supports life science ventures by identifying and empowering science-backed projects and proactively guiding them to fruition

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Gamida Cell's lead product, omidubicel, has recently successfully completed a phase III clinical trial in hematological malignancies.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer and infectious diseases.
+

Cadent Therapeutics

Cadent Therapeutics is developing innovative drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company discovering and developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities.
+

Biokine

Biokine Therapeutics is developing novel therapeutics to treat cancer. It's lead product, motixafortide (formerly BL-8040), is licensed to BiolineRx and is currently in phase III clinical development.

See complete portfolio

Press Releases

2020

18

Nov

Biokine: BioLineRx Initiates Phase 1b Trial of Motixafortide in Acute Respiratory Distress Syndrome Secondary to COVID-19 and Other Respiratory Viruses
10

Nov

Tel-Aviv District Court Approves CBI’s Share Buyback
10

Nov

MediWound: 24-month data from NexoBrid®’s Pivotal DETECT trial and Q3 2020 Financial Results
05

Nov

Gamida Cell: New Data on Omidubicel in Patients with Severe Aplastic Anemia
05

Nov

Gamida Cell: Updated Data from Phase 1 Study of GDA-201 in non-Hodgkin Lymphoma
01

Nov

Biokine: BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide in Stem Cell Mobilization

Read all Press Releases